Fig. 5.

Increases in NK- and PD-1 ⁺ T-cell proliferation following gemcitabine correlate with clinical outcome

Kaplan–Meier (KM-) curves showing differences in progression free- (PFS) and overall survival (OS) between patients exhibiting an increase (green) or decrease (red) of selected immune parameters following gemcitabine (GEM). 22 gemcitabine-treated patients were included in the analysis. Log-rank tests were applied. NK = natural killer, PD-1 = programmed cell death protein 1, HR = hazard ratio, CI = confidence interval.